<DOC>
	<DOCNO>NCT00938743</DOCNO>
	<brief_summary>According available data individual ADHD impair drive ability improve stimulant medication . The impact specific noradrenalin-reuptake-inhibitor atomoxetine drive ability patient ADHD never study far . The present study aim evaluate effect atomoxetine treatment patient ADHD practical driving ability assess standardized driving test , structure one-week driving diary driving related neuropsychological processing especially different aspect attention executive function assess neuropsychological test battery design assessment driver fitness . A functional magnetic resonance imaging ( fMRI ) - investigation also perform begin 10-week treatment atomoxetine . The study conduct single-blind placebo control parallel group design cooperation academic Adult ADHD-outpatient clinic Central Institute Mental Health , Mannheim Institute Legal Traffic Medicine University Heidelberg , Germany . It expect treatment atomoxetine improve practical driving ability drive related neuropsychological processing . It expect risk take impulsive decision making reduce sustained attention overview complex traffic situation improve driving .</brief_summary>
	<brief_title>Driving Adults With Attention-deficit/Hyperactivity Disorder ( ADHD ) Before During Treatment With Atomoxetine</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>1 . Informed Consent Form sign patient . 2 . Patients 1650 year age inform consent document obtain ( Visit 1 ) . 3 . Patients judge investigator reliable keep appointment clinic visit test , include venipuncture examination , require protocol . 4 . Patients must meet DSMIVTR criterion ADHD assess Conners ' Adult ADHD Diagnostic Interview DSMIV ( CAADID ) KIDDIESADDSPL respectively accord expert consensus . 5 . Patients must also significant evaluation current ADHD use Conners ' Adult ADHD Rating Scale Observer : Screening Version ( CAARSO : SV ) Conners ' Rating Scales Revised ( CRSR ) : SV respectively 6 . Patients must CGIADHDS score 4 point ( moderate symptom ) Visit 1 . 7 . Patients age 18 old must valid driver 's license . 8 . Patients must laboratory result assessed Visit 1 , include serum chemistry , haematology , thyroid function , show significant abnormality . Significant would include laboratory deviation require acute medical intervention medical evaluation . 9 . Patients must negative urinary drug screen Visit 1 . 10 . Patients must medical history heart disease could destabilize increase heart rate blood pressure . The screening electrocardiogram ( ECG ) perform Visit 1 must show significant abnormality . Significant would include heart rate le 40 bpm 120 bpm respectively , disturbance rhythm conduction well ECGfindings point myocardial infarction . 11 . Females childbearing potential defined woman surgically sterilize menarche 1 year postmenopause must test negative pregnancy Visit 1 base urinary pregnancy test agree use reliable method birth control ( e.g. , oral contraceptive , reliable barrier method birth control like diaphragm , intrauterine device ; partner vasectomy abstinence ) study . The exclusion criterion design eliminate patient meet study population criterion whose participation study would inappropriate due underlie safety issue ensure patient participate study stable physical condition . They design maintain consistency approve global labeling atomoxetine . Patients exclude study meet follow criterion : 1 . Patients investigator site personnel directly affiliate study , immediate family investigator site personnel directly affiliate study . Immediate family define spouse , parent , child , sibling , whether biological legally adopt . 2 . Patients meet full DSMIV diagnostic criterion history bipolar psychotic disorder , current major depression , current generalize anxiety disorder panic disorder exclude study . Assessment do clinical history Structured Clinical Interview DSMIV AxisI disorder ( SCID ) . 3 . Patients currently use alcohol , drug abuse , prescribed overthecounter medication manner investigator considers indicative abuse meet DSMIVTR criterion substance abuse , assess clinical history Structured Clinical Interview DSMIV ( SCID ) . Patients must use drug abuse illicitly obtain prescription drug study , urine drug screen may obtain time study . Alcohol use discourage , , investigator 's judgment , patient use alcohol excess , patient discontinue . 4 . Patients , opinion investigator , serious suicidal homicidal risk . 5 . Patients organic brain disease , example , dementia , traumatic brain injury residual , history seizure disorder ( except febrile seizure childhood ) . 6 . Patients history severe allergies one class medication multiple adverse drug reaction . 7 . Patients known history narrow angle glaucoma . 8 . Males prostatic symptom . 9 . Patients significant medical condition likely become unstable trial would likely destabilize treatment atomoxetine , ( example , cardiovascular disease would aggravate increased heartrate ) , require treatment excluded medication . 10 . Patients medical condition take medication daily basis ( example albuterol , inhalation aerosol ) sympathomimetic activity . 11 . Patients hypertension . For purpose protocol , hypertension define average systolic diastolic blood pressure , measure least 2 separate occasion , great equal 140/90 . Patients whose blood pressure control nonexcluded medication eligible inclusion . 12 . Patient take psychotropic medication daily basis within 2 week Visit1 . However , zolpidem dose 10 mg may use intermittently need insomnia provide use 3 time weekly . 13 . Patients receive regular treatment within last 30 day drug receive regulatory approval indication take antipsychotic medication time study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>ADHD</keyword>
	<keyword>adult</keyword>
	<keyword>drive performance</keyword>
	<keyword>atomoxetine</keyword>
</DOC>